Related references
Note: Only part of the references are listed.Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
Riyaz Shah et al.
CLINICAL LUNG CANCER (2020)
Sequential afatinib and osimertinib in patients withEGFRmutation-positive non-small-cell lung cancer: final analysis of the GioTag study
Maximilian J. Hochmair et al.
FUTURE ONCOLOGY (2020)
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Martin Schuler et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
Tianli Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
Maximilian J. Hochmair et al.
FUTURE ONCOLOGY (2019)
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Ping-Chih Hsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Maximilian J. Hochmair et al.
TARGETED ONCOLOGY (2019)
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
Keunchil Park et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer
Namita Sharma et al.
CANCER TREATMENT REVIEWS (2018)
NCCN Guidelines® Insights Non- Small Cell Lung Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2017)
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
J. C. -H. Yang et al.
ANNALS OF ONCOLOGY (2016)
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Yoshihisa Kobayashi et al.
CANCER SCIENCE (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Vera Hirsh
BIODRUGS (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy
Katsuyuki Hotta et al.
CANCER (2007)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)